Sibyll Escher is a chemist and is working at MSD for 23 years (with more than 13 years antiinfective experience). She is responsible in her role as a Director Medical Affairs Antiinfectives (antibiotics, antimycotics, CMV) at MSD for:
(I) Initiation and supervision of medical research projects (local non-interventional studies and investigator-sponsored trials) including publications.
(II) Medical input to scientific studies of phases I-IIIb as well as analysis and classification of the data into a medical context.
(III) Writing and support regarding medical contents in health technology assessments and value dossiers and close cross-functional cooperation with in-house departments and external stakeholder.
(IV) Conception, organisation and implementation of scientific symposia, advisory boards, study meetings.
(V) Providing scientific information to external scientific experts and healthcare stakeholders.
(VI) Accompaniment and development of new antiinfectives from phase I to late stage.
Merck & Co., Inc., Kenilworth, New Jersey, USA, is known as “Merck” in the United States, Canada & Puerto Rico. We are known as “MSD” in Europe, Middle East, Africa, Latin America & Asia Pacific. We are a global biopharmaceutical leader with a diverse portfolio of prescription medicines, oncology, vaccines, antiinfectives and animal health products.
We are driven by our purpose to develop and deliver innovative products that save and improve lives. With 69,000 employees operating in more than 140 countries, we offer state-of-the-art laboratories, plants and offices that are designed to inspire our employees as we learn, develop and grow in our careers. We are proud of our 125 years of service to humanity and continue to be one of the world’s biggest investors in Research & Development.
For over 80 years, MSD has played a significant role in vaccine and antibiotic research and development (R&D). Today, MSD is one of only a few large pharmaceutical companies that has continued to pursue R&D to develop new medicines and vaccines that prevent and treat bacterial infections. Our broad portfolio spans both human and animal health and includes antibiotics, vaccines and novel approaches to reduce the need for antibiotics. We continue to invest in both early- and late stage R&D.
Sibyll Escher has a lot of experience in bringing antiinfectives to the German market in her role as a Director Medical Affairs. With her expertise in cross-functional cooperation and networking with different in-house departments and external scientific experts from leading universities, policy & healthcare stakeholders and, additionally, her knowledge about medical input in scientific studies of phases I-IIIb and health technology assessments and value dossiers she can support this network from a pharmaceutical company perspective.